Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
Neurogene Shares Enrollment Locations and Information for Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome (Community Letter)
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome (Community Letter)
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Updates on Program & Risk Mitigation Strategies (Community Letter)
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
